Cullinan Therapeutics
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- -
- Employees
- 85
- Market Cap
- $1B
- Introduction
Cullinan Management, Inc. is a biopharmaceutical company engages in developing oncology and immuno-oncology therapies. The company was founded by Patrick R. Baeuerle on 15 September, 2016 and is headquartered in Cambridge, MA.
FDA approves Cullinan's lupus drug for Phase 1 trials
Cullinan Therapeutics received FDA approval for Phase 1 trials of CLN-978, targeting systemic lupus erythematosus (SLE). The trial aims to assess safety and efficacy in patients with moderate to severe SLE. CLN-978, a novel bispecific T cell engager, shows promise in preclinical studies. The company also progresses in cancer treatment trials and strengthens its leadership team.
© Copyright 2025. All Rights Reserved by MedPath